Watch Elekta AB (publ) for free: we tell you when fair value or trend changes.

Elekta AB (publ) (EKTA-B) fair value: what the stock is really worth

As of Oct 19, 2026: fair value (intrinsic value) of Elekta AB (publ) stock SEK 8.81, price SEK 55.95, upside -84.3%, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · SE · ISIN SE0000163628

Thin data Oct 2, 2026

Elekta AB (publ)

EKTA-B · ST

Stretched ValuationStrong overvaluation with only moderate quality.

Our calculation puts a fair price 84% below what the stock costs today.

Low debt

Generates free cash flow

4.3% dividend yield · Cash covered

Quality 52/100

Mixed Growth (revenue 5y +4.0 %/yr in SEK)

Mixed vs. peers (7/13)

Fair value kr 8.81 · Strongly overvalued (−84.3%)

Loss-making · -2.2% net margin (TTM)

Narrow moat 25/100

Thin data

Structural break

26 models, one by oneBear kr 8.81 to bull kr 13.84 Growth analysisrevenue history, year by year Quality 52/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Elekta AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range kr 41.49 – kr 109.67 · fair‑value band kr 8.81 – kr 13.84 · the kr 55.95 price screens above the kr 8.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Elekta AB (publ) in your weekly email

Every Wednesday you see whether Elekta AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Show moreShow less

The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions.

It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite.

In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer.

Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions.

Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance.

Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Stock analysis

Elekta AB (publ) (EKTA-B) currently trades at kr 55.95, while our model-based Fair Value estimate is kr 8.81, 84.3% below the price, so the stock looks overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of kr 58.07 per share, and 5 of the 13 models we run sit above the kr 55.95 price.

Bear case: the Earnings-Based group reads lowest at kr 5.73, and 8 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: kr 8.81 (bear) to kr 13.84 (bull), the price of kr 55.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Elekta AB (publ) reported revenue of 16.7B SEK in FY2026 versus 14.5B SEK in FY2022, a compound +3.5%/yr. Reported net income was −520M SEK in FY2026.

Key figures

Market cap 21.5B SEK (≈ $2.2B) Mid · P/S ratio 1.21 · EPS (TTM) kr −0.9500 · Dividend yield 4.3% · Net margin −2.2% · Return on equity −4.3% · Return on assets (EBIT) 4.5% · Operating margin 10.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).

What moves the price

The share trades about 11% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −84%, EKTA-B screens richer than that median.

Fair Value models

Bear kr 8.81 Fair Value kr 8.81 Bull kr 13.84

Price kr 55.95 · Upside -84.3%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF kr 73.18 kr 110.20 kr 163.79 80

Growth DCF kr 74.41 kr 107.32 kr 152.21 79

Owner Earnings kr 33.20 kr 50.14 kr 74.67 76

All 13 models by family

DCF Models

FCF DCF kr 73.18 kr 110.20 kr 163.79 80

Owner Earnings kr 33.20 kr 50.14 kr 74.67 76

5Y Revenue Exit kr 32.78 kr 41.29 kr 50.84 74

5Y EBITDA Exit kr 53.39 kr 79.42 kr 108.86 75

10Y Revenue Exit kr 47.01 kr 58.07 kr 70.74 68

10Y EBITDA Exit kr 60.14 kr 83.85 kr 113.68 69

Earnings-Based

EPV kr 4.88 kr 5.73 kr 6.47 74

Multiples

EV/EBIT kr 3.79 kr 8.81 kr 13.84 62

EV/EBITDA kr 36.83 kr 52.86 kr 68.90 67

EV/Revenue n/a kr 4.09 kr 8.70 50

Growth DCF

Growth DCF kr 74.41 kr 107.32 kr 152.21 79

Rev-Margin DCF kr 32.78 kr 42.58 kr 54.22 74

Economic Profit

ROIC Compounder kr 4.88 kr 5.73 kr 6.47 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19

How much profit the company makes from its sales and capital

Quality Growth 30

Are margins and returns getting better?

Cashflow 73

Do the profits arrive as real cash?

Financial strength 30

Debt, balance sheet and risk of trouble

Investment 100

Does it invest with discipline instead of growing at any price?

Low Volatility 53

How calm the share price moves, does not count

Momentum 52

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 62

Distance to the 52-week high, does not count

New shares 79

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−7.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−0.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.0%

Start year 2021 (pandemic). Over 10 years: +4.1% a year

Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.8%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

13.8% (2021) → 2.6% (2026)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far and less than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−2.8%

The company could shrink this much every year for the next five years and today's price would still be justified.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+3.7%

Yearly sales growth analysts expect, extended to five years.

After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about −4.7% a year for the price and +1.7% for the forecasts.

Forecast 2027 (sales)+3.1%

Forecast 2028 (sales)+4.3%

Projected 2029 (sales)+4.0%

Projected 2030 (sales)+3.7%

Projected 2031 (sales)+3.4%

EKTA-B screens overvalued: fair value 84% below the price. Compare with Abbott Laboratories, →

Compare Elekta AB (publ) with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks

Beats the industry median on 7/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 52 · Above median

Fair Value upside −84.3% · Bottom 25%

Profitability

Return on assets −1.9% · Below median

Net margin (12 months) −2.2% · Below median

Operating margin (12 months) 10.5% · Above median

Growth and dividend

Revenue growth (quarter YoY) −3.0% · Bottom 25%

Dividend yield (12 months) 4.3% · Top 25%

Balance sheet

Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.02× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (12 months) 1.29× · Cheapest 25%

Price / free cash flow 9.2× · Cheapest 25%

EV/EBITDA 11.7× · Cheaper than median

PEG 0.38× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 10

FUTURE (revenue growth)0 · sector 33

PAST (return on equity)0 · sector 16

HEALTH (low debt)76 · sector 98

DIVIDEND (yield)86 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Stryker Corporation SYK	$282.60	$310.86	+10%	vs EKTA-B
Boston Scientific Corporation BSX	$43.00	$47.30	+10%	vs EKTA-B
DexCom, Inc DXCM	$84.11	$92.52	+10%	vs EKTA-B
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥166.00	¥182.60	+10%	vs EKTA-B
GE HealthCare Technologies Inc GEHC	$65.74	$70.37	+7%	vs EKTA-B
Edwards Lifesciences Corporation EW	$86.60	$81.94	−5%	vs EKTA-B
Siemens Healthineers AG SHL	€41.45	€35.19	−15%	vs EKTA-B
Abbott Laboratories, ABT	$102.61	$74.79	−27%	vs EKTA-B
Medtronic plc MDT	$91.93	$65.61	−29%	vs EKTA-B
Koninklijke Philips N.V PHIA	€22.18	€15.23	−31%	vs EKTA-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elekta AB (publ) · Fair Value
kr 8.81 −84%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/EKTA-B" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Elekta AB (publ) · Fair Value</span><br><b style="font-size:20px">kr 8.81</b> <span style="color:var(--red);font-weight:700;font-size:14px">−84%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Elekta AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/EKTA-B

Frequently asked questions

Is Elekta AB (publ) (EKTA-B) overvalued or undervalued?

As of Oct 2, 2026, our model estimates a fair value of kr 8.81 versus a price of kr 55.95, about −84% upside (overvalued).

What is the fair value of EKTA-B?

Our model-based fair value for Elekta AB (publ) is kr 8.81 (as of Oct 2, 2026), built from audited fundamentals. The current price: kr 55.95.

What is the quality score of EKTA-B?

Elekta AB (publ) has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Elekta AB (publ) (EKTA-B)?

Our model-based price target is the fair value of kr 8.81 (as of Oct 2, 2026) from 13 valuation models. Cautious scenario kr 8.81, optimistic scenario kr 13.84. It is a calculation from audited fundamentals, not an analyst target.

What is the Elekta AB (publ) stock forecast for 2026?

Our models put fair value at kr 8.81, about −84% upside versus a price of kr 55.95 (overvalued). Cautious scenario kr 8.81, optimistic scenario kr 13.84. The calculation is refreshed regularly with new filings.

What is the revenue of Elekta AB (publ) (EKTA-B)?

Elekta AB (publ) reported trailing-twelve-month revenue of about 16.6B SEK (latest available figure, as of Oct 2, 2026).

Does Elekta AB (publ) pay a dividend?

Elekta AB (publ) currently shows a dividend yield of 4.29% relative to its recent price (as of Oct 2, 2026).

What growth is priced into Elekta AB (publ) (EKTA-B)?

For today's price to be fair in a discounted-cash-flow model, Elekta AB (publ) would have to grow free cash flow by -2.8 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.0 % per year. As of Oct 2, 2026.

What discount rate (WACC) does the fair value of EKTA-B use?

Our models discount Elekta AB (publ) at 9.5 %: a base by market capitalisation (mid), damped by beta 0.98, country premium for Sweden. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Elekta AB (publ) that is -2.8 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.

How much growth has Elekta AB (publ) (EKTA-B) delivered so far?

Over the past 5 years revenue at Elekta AB (publ) grew +4.0 % a year. The price currently implies -2.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Elekta AB (publ) (EKTA-B) growing?

The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into Elekta AB (publ) (-2.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Elekta AB (publ) (EKTA-B)?

The free-cash-flow yield on the price is 10.92 %: that much free cash flow Elekta AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Elekta AB (publ) (EKTA-B)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elekta AB (publ) it is kr 8.81 per share (as of Oct 2, 2026), against a price of kr 55.95. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).

Is Elekta AB (publ) stock overvalued or undervalued in 2026?

As of Oct 2, 2026, EKTA-B trades above its calculated fair value: price kr 55.95, fair value kr 8.81, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of EKTA-B?

No. The price is what the market pays today (kr 55.95); the fair value is what the company's own numbers justify (kr 8.81). For Elekta AB (publ) the two are kr 47.14 per share apart. That gap is exactly why we show both numbers side by side.

How much is Elekta AB (publ) worth?

The market values Elekta AB (publ) at about 21.5B SEK (market capitalisation, as of Oct 2, 2026). Per share that is kr 55.95; our models calculate a fair value of kr 8.81 per share.

What do the bullish and bearish scenarios say about EKTA-B?

Our models span a range for Elekta AB (publ): cautious scenario kr 8.81, base kr 8.81, optimistic kr 13.84 per share (as of Oct 2, 2026, price kr 55.95). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of EKTA-B?

The PEG ratio of Elekta AB (publ) is 0.38 (P/E divided by earnings growth, as of Oct 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Elekta AB (publ) (EKTA-B)?

Balance-sheet figures for Elekta AB (publ) (as of Oct 2, 2026): return on equity −4.3%, debt of 0.48 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.

How far is EKTA-B from its 52-week high?

Elekta AB (publ) trades at kr 55.95, about 11% below its 52-week high of kr 62.55 and 35% above the low of kr 41.49 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 8.81 is for.

Which stocks are comparable to Elekta AB (publ)?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Elekta AB (publ) stock attractive at the current price?

The data as of Oct 2, 2026: price kr 55.95, calculated fair value kr 8.81 (−84%), Quality Score 52/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of EKTA-B calculated?

We run Elekta AB (publ) through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 8.81, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.9 % above its aggregate fair value. Elekta AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Elekta AB (publ) (EKTA-B)?

The closing price on Oct 19, 2026 was kr 55.95. Our model-based fair value is kr 8.81, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Elekta AB (publ) right now?

The price sits above even our optimistic bull case (kr 13.84). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Where does the earnings growth of Elekta AB (publ) (EKTA-B) come from?

Earnings per share at Elekta AB (publ) grew +13.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.1 %, EBIT margin +3.7 %, tax rate +0.9 %, residual (interest, one-offs) +1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Elekta AB (publ)

How large is the market capitalisation of Elekta AB (publ) (EKTA-B)?

The market capitalisation of Elekta AB (publ) is 21.5B SEK (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Elekta AB (publ) (EKTA-B)?

The price-to-sales ratio of Elekta AB (publ) is 1.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Elekta AB (publ) (EKTA-B)?

Earnings per share at Elekta AB (publ) are kr −0.9500. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Elekta AB (publ) (EKTA-B)?

The dividend yield of Elekta AB (publ) is 4.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Elekta AB (publ) (EKTA-B)?

The net margin of Elekta AB (publ) is −2.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Elekta AB (publ) (EKTA-B)?

The return on equity (ROE) of Elekta AB (publ) is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Elekta AB (publ) (EKTA-B)?

On an EBIT basis the return on assets of Elekta AB (publ) is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Elekta AB (publ) (EKTA-B)?

The operating margin of Elekta AB (publ) is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Elekta AB (publ) (EKTA-B)?

Revenue at Elekta AB (publ) is growing −3.0% versus a year earlier (3y avg −0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Elekta AB (publ) (EKTA-B)?

Earnings per share at Elekta AB (publ) are growing +146% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Elekta AB (publ) (EKTA-B) carry?

The net debt of Elekta AB (publ) is 4.1B SEK (fiscal year 2026, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Elekta AB (publ) in the live analysis

One click puts Elekta AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.